SEC	Form	4
-----	------	---

F	0	R	N	1	4
---	---	---	---	---	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	rden
hours per response:	0.5

Section obligat	this box if no l n 16. Form 4 o ions may conti tion 1(b).		STAT		ed pur	rsuant	to Sectio	on 16(a	a) of the Se	ecurit	NEFICIA ies Exchang mpany Act o	ge Act o	of 193		HIP	Estim		er: verage burde sponse:	3235-0287 n 0.5
1. Name and Address of Reporting Person [*] Silva Paul M				2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner V Officer (give title Other (specify								
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 02/02/2012								X Onicer (give the Other (spechy below) below) SVP & Corp Controller					
130 WAN (Street) CAMBR (City)		1A State)	02139 (Zip)		4.1	If Ame	endment,	Date o	of Original	Filed	(Month/Da	y/Year)		Line)	K Form fi	led by One led by Mor	e Repo	(Check App orting Perso I One Repo	n
4 Tal 64			ble I - Nor	1					quired,	Dis	-			-					7. Nature of
Date		2. Trans Date (Month/	h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		e, Transaction Code (Instr					Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following Reported		n: Direct r Indirect Istr. 4)	Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A (D	A) or D)	Price	Transaction(s) (Instr. 3 and 4)				(instr. 4)		
Common	Stock			02/0	<mark>2/20</mark> 1	12			Α		4,500((1)	Α	\$0.01	\$0.01 13,000 D			D	
Common	Stock		Table II -	Doriva	tivo	500	urition	A			acad of	or Pr	onof	icially.		380		Ι	401(k)
											convertit				Owneu				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution Date, if any ((Month/Day/Year)		ransaction of ode (Instr. De) Sec (A) Dis of (of Derivat Securit Acquire (A) or Dispose of (D) (I	of Ex Derivative (M Securities Acquired		i. Date Exercisable and :xpiration Date Month/Day/Year)		7. Title and of Securities Underlying Derivative S (Instr. 3 and		es Security 1 4)	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)
					Code			Date Exercisab	Date Exp Exercisable Dat				Amount or Number of Shares						

Explanation of Responses:

\$37.86

1. Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection.

05/02/2012(2)

2. Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012.

Remarks:

Stock

Option

Valerie L Andrews, Attorney-In-Fact

18,000

Commor

Stock

02/01/2022

02/06/2012

18,000

D

** Signature of Reporting Person Date

\$0.00

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/02/2012

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

18,000